暴涨超100%！盘中突发，暂停交易

Core Viewpoint - The A-share market experienced narrow fluctuations, with the cross-border payment concept gaining significant attention, while the Hong Kong market showed a relatively weak performance, particularly in the pharmaceutical sector, highlighted by the dramatic rise of Xintai Medical's stock before its trading suspension [1][3][10]. Group 1: Market Performance - The A-share market showed overall narrow fluctuations, with the Shanghai Composite Index rising by 0.31% and the Shenzhen Component Index and ChiNext Index falling by 0.41% and 0.98%, respectively [3]. - The cross-border payment concept sector led the gains, with a peak increase of over 4%, making it the biggest highlight of the morning session [3][4]. Group 2: Xintai Medical - Xintai Medical's stock surged, with an intraday increase exceeding 100%, before being suspended with a still substantial rise of 47.19% at the time of suspension [1][10]. - The company is a significant player in the structural heart disease intervention medical device industry in China, with a product line that includes various heart defect closure devices and has a presence in over 50 countries [11]. - Xintai Medical projected a net profit of approximately 230 million to 260 million yuan for 2024, a significant increase from 152 million yuan in 2023, primarily due to a substantial rise in sales of its bioabsorbable closure devices [11]. Group 3: Related Companies - Other companies in the cross-border payment sector, such as Xincheng Technology and Kela Software, also saw significant intraday gains, with some stocks hitting the daily limit [3][4]. - The pharmaceutical sector, including companies like Weir Pharmaceuticals and Baida Group, experienced consecutive trading halts due to significant price increases, prompting risk warnings to investors [5][6][7].